v3.25.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Total revenue $ 228,385 $ 233,255 $ 237,277
Total cost of revenue 128,754 133,923 133,404
Gross margin 99,631 99,332 103,873
Operating costs and expenses:      
Selling, general and administrative 148,978 146,880 120,055
Engineering and development 17,710 18,040 15,722
Impairment loss 63,809 49,569  
Total operating costs and expenses 230,497 214,489 135,777
Loss from operations (130,866) (115,157) (31,904)
Other income (expense):      
Investment income 9,895 10,577 8,474
Interest expense (4,108) (5,503) (6,142)
Gain on extinguishment of debt, net 18,505 5,679  
Other income (expense), net (6,906) 5,056 (5,522)
Total other income (expense), net 17,386 15,809 (3,190)
Loss before provision for income taxes (113,480) (99,348) (35,094)
Provision for income taxes (1,276) (239) (2,239)
Net loss (114,756) (99,587) (37,333)
Paid-in-kind dividend on Series C convertible preferred stock (8,000) (8,000) (8,000)
Net loss attributable to common stockholders $ (122,756) $ (107,587) $ (45,333)
Net loss per share - basic (in dollar per share) $ (2.49) $ (2.21) $ (0.93)
Net loss per share - diluted (in dollar per share) $ (2.49) $ (2.21) $ (0.93)
Weighted average shares outstanding - basic (in shares) 49,349,624 48,737,377 48,987,295
Weighted average shares outstanding - diluted (in shares) 49,349,624 48,737,377 48,987,295
Life sciences services      
Total revenue $ 153,660 $ 144,087 $ 133,879
Total cost of revenue 85,206 81,820 75,187
Life sciences products      
Total revenue 74,725 89,168 103,398
Total cost of revenue $ 43,548 $ 52,103 $ 58,217

Source